These findings suggested that PRDM9-mediated suppression of H3K4me3 reduces ACTN2 expression, promoting VSMC dysfunction and aneurysm progression, highlighting potential therapeutic targets for aneurysm treatment. Here, ACTN2 is linked to aneurysm.